Practical Adverse Management Strategies With Intravenous Amivantamab

Video content above is prompted by the following:

• Shifting focus to cardiac adverse effects, specifically venous thromboembolism, or VTE, how do you approach risk assessment and prophylaxis in your practice?
  • What factors do you consider when deciding on pharmacological vs nonpharmacological prophylaxis?
  • What is your approach to VTE management with amivantamab?

• What strategies have you found effective in educating patients about early signs of VTE and the potential benefits of prophylaxis?
  • In your experience, how do patients typically respond to discussions about VTE risk and potential prophylactic measures?
  • In these conversations, how do you balance the potential benefits of prophylaxis with patient concerns about additional medications or injections?